Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study

A.H. Önder & M.M. Çatlı · 2025

Links
Authors
A.H. Önder, M.M. Çatlı